Bank of New York Mellon Corp trimmed its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 69.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 985,789 shares of the medical device company’s stock after selling 2,257,139 shares during the quarter. Bank of New York Mellon Corp owned approximately 1.13% of DexCom worth $48,229,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently modified their holdings of DXCM. Bank of Montreal Can grew its stake in DexCom by 69.2% during the second quarter. Bank of Montreal Can now owns 31,403 shares of the medical device company’s stock worth $2,296,000 after buying an additional 12,847 shares during the last quarter. Aperio Group LLC grew its stake in DexCom by 19.1% during the second quarter. Aperio Group LLC now owns 8,870 shares of the medical device company’s stock worth $649,000 after buying an additional 1,425 shares during the last quarter. Public Employees Retirement Association of Colorado grew its stake in DexCom by 0.4% during the second quarter. Public Employees Retirement Association of Colorado now owns 18,613 shares of the medical device company’s stock worth $1,362,000 after buying an additional 83 shares during the last quarter. Janney Montgomery Scott LLC grew its stake in DexCom by 9.2% during the second quarter. Janney Montgomery Scott LLC now owns 2,959 shares of the medical device company’s stock worth $216,000 after buying an additional 250 shares during the last quarter. Finally, Bbva Compass Bancshares Inc. grew its stake in DexCom by 1.9% during the second quarter. Bbva Compass Bancshares Inc. now owns 3,670 shares of the medical device company’s stock worth $268,000 after buying an additional 69 shares during the last quarter.

In other DexCom news, EVP Andrew K. Balo sold 6,490 shares of the firm’s stock in a transaction that occurred on Wednesday, November 29th. The shares were sold at an average price of $60.00, for a total value of $389,400.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Kevin R. Sayer sold 6,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 20th. The shares were sold at an average price of $69.34, for a total transaction of $416,040.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 37,954 shares of company stock worth $2,266,296. Insiders own 1.70% of the company’s stock.

Several analysts have weighed in on DXCM shares. Northland Securities cut shares of DexCom from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $85.00 to $60.00 in a research note on Thursday, September 28th. Wedbush reaffirmed a “buy” rating and set a $76.00 price objective on shares of DexCom in a research note on Wednesday, October 4th. Zacks Investment Research cut shares of DexCom from a “hold” rating to a “sell” rating in a research note on Tuesday, October 24th. Robert W. Baird reissued a “hold” rating and set a $79.00 price target on shares of DexCom in a research note on Sunday, September 10th. Finally, Morgan Stanley decreased their price target on shares of DexCom from $72.00 to $52.00 and set a “neutral” rating on the stock in a research note on Friday, November 3rd. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and fourteen have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $70.69.

Shares of DexCom, Inc. (NASDAQ DXCM) opened at $57.88 on Tuesday. DexCom, Inc. has a 52 week low of $42.62 and a 52 week high of $88.80. The company has a debt-to-equity ratio of 0.84, a quick ratio of 5.50 and a current ratio of 5.86.

COPYRIGHT VIOLATION NOTICE: “DexCom, Inc. (DXCM) Shares Sold by Bank of New York Mellon Corp” was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://theolympiareport.com/2017/12/05/dexcom-inc-dxcm-shares-sold-by-bank-of-new-york-mellon-corp.html.

DexCom Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.